

Datasheet: HCA401

Description:	HUMAN ANTI OCRELIZUMAB
Specificity:	OCRELIZUMAB
Other names:	Ocrevus
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD50989ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Ocrelizumab

Specificity **Human Anti-Ocrelizumab Antibody, clone AbD50989ia** is a paratope specific, inhibitory, anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug ocrelizumab and its biosimilar products. Consequently, this antibody can be used to measure free ocrelizumab levels in serum from patients.

Clone AbD50989ia (HCA401) is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a positive control or calibrator in an anti-drug antibody (ADA) assay. It does not cross-react with the antibody drug rituximab (Rituxan).

Ocrelizumab (trade name Ocrevus) is a monoclonal IgG1/kappa antibody (VH3/ κ 1). In vitro, it binds to CD20 cell surface molecules on target cells thereby inducing immune effector mechanisms such as antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. In vivo, ocrelizumab selectively and effectively depletes CD20⁺ B cells. Hence, it is an immunosuppressive drug. Ocrelizumab is used to treat primary progressive multiple sclerosis and relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).

Affinity The monovalent intrinsic affinity of Human anti-Ocrelizumab Antibody, clone AbD50989ia was measured as $K_D = 0.7$ nM by real time, label-free molecular interaction analysis on immobilized ocrelizumab.

ELISA This product may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera together with [HCA399](#) and [HCA400](#).

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Acknowledgements This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Ocrevus is a registered trademark of Genentech/ Roche and Biogen.
Rituxan is a registered trademark of Genentech and Biogen.

Health And Safety Information Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/HCA401>
10040

Licensed Use For *in vitro* research purposes and for commercial applications for the provision of *in vitro* testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI OCRELIZUMAB \(HCA400\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI OCRELIZUMAB \(TZA044\)](#)

[HUMAN ANTI OCRELIZUMAB \(TZA045\)](#)

[HUMAN ANTI OCRELIZUMAB:HRP \(TZA045P\)](#)

[HUMAN ANTI OCRELIZUMAB \(HCA399\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M430251:240503'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)